The Anti-SARS-CoV-2 IgG Antibody Response of Participants Vaccinated with Different Vaccine Combination

Abstract

Introduction: In current literature, there are lots of description about the new Coronavirus, named as SARS-CoV-2 by World Health Organization (WHO). Basically, SARS-CoV-2 has been identified as the etiological agent of COVID-19 disease which was reported a group of patients with pneumonia of unknown cause in Wuhan, China, in December 2019. In this work, our aim was to investigate the anti-S1 IgG response that occurs after different kinds and different doses of SARS-CoV-2 vaccines and the demographic characteristics of participants. Materials and Methods: A total of 299 participants were included in this study to detect the Anti-SARS-CoV-2 IgG antibody. The only inclusion criteria for this study were being vaccinated minimum 2-doses of any SARS-CoV-2 vaccine. For detecting the antibody levels of participants, Anti-SARS-CoV-2 ELISA (IgG) test kit which applies a recombinant S1 subunit of the SARS-CoV-2 spike protein, enabling detection of IgG antibodies was used. Results: Out of 299 individuals, 128 (42.8%) were male and 171 (57.2%) were female in our study. The mean age of individuals 35.11±8.13 (minimum: 19 and maximum: 59). The lowest antibody levels were belong to Group 2 and Group 3 (138.66±25.41, and 82.09±63.42 IU/ml, respectively), while the highest antibody levels were belong to Group 6 (239.35±18.73 IU/ml). Discussion: According to our result, a significantly higher humoral immunogenicity of the SARS-CoV-2 BioNTech compared with the CoronaVac vaccine. A significant increase in serological response was achieved with the 3rd or 4th dose of vaccine; however, it had better to be vaccinated with BioNTech after 2nd dose of COVID-19 vaccine.